Genscript SARS-CoV-2 Spike protein (RBD, L452R, T478K, Avi & His Tag)-HRP

Genscript SARS-CoV-2 Spike protein (RBD, L452R, T478K, Avi & His Tag)-HRP - GSCRPT (Additional S&H or Hazmat Fees May Apply)

List Price $120.00 Your Price $120.00

HOW MUCH YOU SAVE:

0.00 %

Product Introduction

Species

SARS-CoV-2

Protein Construction

Spike RBD [Arg319-Ser591 (L452R, T478K)] Accession # P0DTC2	Avi	Poly-His
N-term		C-term

Conjugate

HRP

Biological Activity

This protein is validated to bind with human ACE2 (Cat. No. Z03516) in functional ELISA assay.

Expression System

CHO

Application

The optimal dilution ratio should be determined by the end user for specific applications.
ELISA 1:1000

Formulation

Supplied as a solution in PBS, pH 7.4, 0.1% ProClin 300.

Storage & Stability

Upon receiving, this product remains stable for up to 3 months at 2-8°C. Protect from light.

Background

Target Background	SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. As of May 2021, three sublineages have been found. Despite its name, B.1.617.3 was the first sublineage of this variant to be detected, in October 2020 in India. This sublineage has remained relatively uncommon compared to the two other sublineages, B.1.617.1 (also known as variant Kappa) and B.1.617.2 (also known as variant Delta), both of which were first detected in December 2020. This variant has the double mutations E484Q and L452R in the spike proteins. Emerging research suggests the variant may be more transmissible than previously evolved ones. Whether the effectiveness of currently-deployed vaccines is affected remains under investigation. Moreover, the sublineage B.1.617.2 has been redesignated as "variant of concern" (VOC-21APR-02) in May 2021, which spreads more quickly than the original version of the virus.
Synonyms	Lineage B.1.617.2; VUI-21APR-02; variant Delta
References	1. Emergence of a novel SARS-CoV-2 strain in Southern California, USA. 2. New California Variant May Be Driving Virus Surge There, Study Suggests. 3. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. 4. Tracking SARS-CoV-2 variants.

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.